An observational study in Multiple Rib Fractures and Isolated Blunt Thoracic Trauma, sponsored by Ankara Etlik City Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.
Sponsored by Ankara Etlik City Hospital · Observational
This prospective observational cohort study will evaluate whether the Geriatric Nutritional Risk Index (GNRI) and Prognostic Nutritional Index (PNI) can predict short-term clinical outcomes in adults aged 65 years or older with isolated blunt thoracic trauma and more than three rib fractures. Participants will be enrolled in the Emergency Department of Ankara Etlik City Hospital. No experimental drug, device, or additional invasive procedure will be used. Routine clinical, laboratory, anthropometric, imaging, and follow-up data will be recorded. The study plans to include 294 participants. The primary outcome is a composite short-term poor clinical outcome, including in-hospital mortality, intensive care unit admission, invasive or non-invasive mechanical ventilation, pneumonia, atelectasis, tube thoracostomy, or hospital stay of 7 days or longer. The prognostic performances of GNRI and PNI will be compared. Secondary outcomes include the individual components of the composite outcome, new pneumothorax or hemothorax, hospital and intensive care unit length of stay, 30-day emergency department revisit, and 30-day mortality.
Older adults with multiple rib fractures may have an increased risk of respiratory complications, intensive care admission, prolonged hospitalization, and mortality after thoracic trauma. Nutritional impairment may contribute to this risk through reduced respiratory muscle strength and impaired immune response. The Geriatric Nutritional Risk Index (GNRI) and Prognostic Nutritional Index (PNI) are practical nutritional assessment tools calculated from routinely available clinical and laboratory data.
This is a prospective, single-center, observational cohort study conducted in the Emergency Department of Ankara Etlik City Hospital. The study will include adults aged 65 years or older who present with isolated blunt thoracic trauma and more than three radiologically confirmed rib fractures. Patients will be evaluated during routine clinical care, and no additional treatment, medication, device, or invasive procedure will be administered for research purposes.
GNRI will be calculated using serum albumin, current body weight, and ideal body weight. PNI will be calculated using serum albumin and the total lymphocyte count. Height, weight, albumin, lymphocyte count, injury characteristics, associated thoracic findings, treatment requirements, hospital course, and clinical outcomes will be recorded prospectively.
The primary analysis will assess the association of GNRI and PNI with the composite short-term poor clinical outcome. The prognostic performances of the two indices will be evaluated using receiver operating characteristic curve analysis, area under the curve comparisons, and optimal cut-off values. Multivariable logistic regression analysis will be used to identify factors independently associated with the primary outcome. Hospital outcomes will be obtained from clinical records. Thirty-day emergency department revisit and mortality data will be obtained from available health records or, when necessary, by telephone follow-up.
Ankara Etlik City Hospital is the lead sponsor of 176 studies on the registry; 77 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population will consist of adults aged 65 years or older presenting to the Emergency Department of Ankara Etlik City Hospital with isolated blunt thoracic trauma and more than three radiologically confirmed rib fractures. Eligible participants will be prospectively enrolled and followed during the index hospitalization and for 30 days after enrollment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults aged 65 years or older presenting to the emergency department with isolated blunt thoracic trauma and more than three radiologically confirmed rib fractures. Participants will be followed prospectively using routinely collected clinical, laboratory, anthropometric, imaging, treatment, and follow-up data. GNRI and PNI will be calculated and their associations with short-term clinical outcomes will be evaluated. No intervention is assigned; participants receive routine clinical care.
Composite In-Hospital Adverse Outcome in Older Adults With Multiple Rib Fractures
Occurrence within the index hospitalization or up to 30 days after enrollment of any of the following: in-hospital mortality; intensive care unit admission; invasive or non-invasive mechanical ventilation; pneumonia; atelectasis; chest tube placement due to pneumothorax or hemothorax; or total hospital length of stay of 7 days or longer.
Time frame: From enrollment through discharge from the index hospitalization, or up to 30 days after enrollment, whichever occurs first.
Intensive Care Unit Admission
Admission to any intensive care unit during the index hospitalization after enrollment.
Time frame: From enrollment through discharge from the index hospitalization or up to 30 days after enrollment, whichever occurs first.
Invasive or Non-invasive Mechanical Ventilation
Initiation of invasive mechanical ventilation through endotracheal intubation or non-invasive ventilation with CPAP or BPAP during the index hospitalization after enrollment. The duration of mechanical ventilation will also be recorded.
Time frame: From enrollment through discharge from the index hospitalization or up to 30 days after enrollment, whichever occurs first.
Pneumonia
New-onset pneumonia during the index hospitalization, defined by a new radiologic pulmonary infiltrate accompanied by at least one clinical finding such as fever, leukocytosis, or purulent respiratory secretions.
Time frame: From enrollment through discharge from the index hospitalization or up to 30 days after enrollment, whichever occurs first.
Atelectasis
Newly developed atelectasis detected by chest radiography or chest computed tomography during the index hospitalization.
Time frame: From enrollment through discharge from the index hospitalization or up to 30 days after enrollment, whichever occurs first.
Tube Thoracostomy
Insertion of a chest tube for the treatment of pneumothorax or hemothorax during the index hospitalization.
Time frame: From enrollment through discharge from the index hospitalization or up to 30 days after enrollment, whichever occurs first.
New-onset Pneumothorax
Newly developed pneumothorax diagnosed during the index hospitalization after enrollment.
Time frame: From enrollment through discharge from the index hospitalization or up to 30 days after enrollment, whichever occurs first.
New-onset Hemothorax
Newly developed hemothorax diagnosed during the index hospitalization after enrollment.
Time frame: From enrollment through discharge from the index hospitalization or up to 30 days after enrollment, whichever occurs first.
Hospital Length of Stay
Total number of days from hospital admission to discharge or in-hospital death during the index hospitalization.
Time frame: From hospital admission until discharge or in-hospital death, whichever occurs first, assessed up to 30 days after hospital admission.
30-Day Emergency Department Revisit
Any repeat visit to the emergency department within 30 days after discharge from the index hospitalization.
Time frame: From discharge from the index hospitalization through 30 days after discharge.
30-Day Post-Discharge Mortality
Death from any cause within 30 days after discharge from the index hospitalization.
Time frame: From discharge from the index hospitalization through 30 days after discharge.
In-Hospital Mortality
Death from any cause during the index hospitalization.
Time frame: From enrollment through 30 days after enrollment.
Plan to share: No — Individual participant data will not be shared with other researchers. The dataset contains sensitive clinical information, and access will be restricted to the study investigators in accordance with the approved ethics protocol and participant confidentiality requirements. Only aggregate results will be reported.
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Sep 2027, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.